Corcept Therapeutics (CORT)
Statistics
| Metric | Value |
|---|---|
| Last Close | $43.96 |
| Blended Price Target | 44.09 |
| Blended Margin of Safety | 0.3% Fairly Valued |
| Rule of 40 (Next) | 46.3% |
| Rule of 40 (Current) | 44.7% |
| FCF-ROIC | 21.7% |
| Sales Growth Next Year | 24.7% |
| Sales Growth Current Year | 23.0% |
| Sales 3-Year Avg | 22.5% |
| Industry | Biotechnology |
Analysis
Corcept Therapeutics stands out as a durable biopharma business with a narrow but defensible niche in cortisol modulation therapies, where Korlym drives predictable, recurring revenue from a loyal patient base treating Cushing's syndrome. This revenue stream exhibits high recurrence due to the chronic nature of the disease, ensuring steady demand without heavy reliance on new prescriptions, while leadership's focus on pipeline expansion bolsters long-term growth prospects beyond the flagship product's patent life. The company's economic moat, rooted in regulatory exclusivity and specialized clinical expertise, provides solid protection against broad competition, though it faces erosion risks from generics post-2037.[1]
Growth durability remains promising, fueled by label expansions, new indications like oncology and neurology, and a total addressable market in endocrine disorders that supports above-market expansion for years, tempered by recent sales deceleration to 11.1% in Q4 2025.[1] Management's capital discipline—evident in zero debt, robust cash reserves, and high ROIC—reinforces resilience, positioning Corcept as a high-quality operator capable of navigating biopharma volatility with disciplined execution.[1][3]
What the Company Does
Corcept Therapeutics develops and commercializes drugs that modulate cortisol, a stress hormone linked to disorders like Cushing's syndrome, cancer, and neurological conditions. Its core product, Korlym (mifepristone), treats hyperglycemia in Cushing's patients by selectively blocking cortisol activity, generating revenue primarily through U.S. sales to endocrinologists and specialized clinics.[1]
Nearly all revenue—over 95%—stems from Korlym, with the remainder from collaborative agreements and minor pipeline contributions; recent Q4 2025 sales hit $202.1 million, underscoring product concentration.[1]
Revenue Recurrence & Predictability
Corcept's revenue is highly transactional yet recurring, tied to ongoing prescriptions for chronic Cushing's syndrome patients who require indefinite treatment. This creates strong predictability, as patient adherence drives repeat fills rather than one-off sales or subscriptions.[1]
Approximately 100% of revenue qualifies as recurring due to the disease's lifelong management needs, scoring Corcept exceptionally high on this metric—far superior to project-based biopharma peers, with minimal seasonal or lumpiness beyond quarterly prescription cycles.[1]
Revenue Growth Durability
Corcept sustained 18.8% CAGR over five years and 25.6% over two years through Korlym uptake, but Q4 2025 growth slowed to 11.1%, signaling maturation in its core Cushing's market.[1] Analysts project 18.9% annual revenue growth, outpacing the U.S. market, driven by label expansions and pipeline candidates like relacorilant for oncology.[2]
Durability hinges on penetrating a vast TAM in cortisol-related diseases, with tailwinds from unmet needs in rare endocrinology; headwinds include generic entry risks post-patent, but new approvals could extend above-market growth for 5–10 years.[1][2]
Economic Moat
Corcept's moat centers on Korlym's regulatory exclusivity as the only FDA-approved cortisol modulator for Cushing's, creating high switching costs for prescribers trained on its profile and patients stabilized on therapy. Intangible assets like clinical data and physician relationships further entrench its position in a niche with few direct rivals.[1]
The moat is narrow but stable, widening via pipeline progress (e.g., relacorilant Phase 3 trials) that builds on cortisol expertise; however, it risks narrowing with patent cliffs and biosimilar threats, lacking scale or cost advantages of larger pharma.[1][2]
Management & Leadership
Corcept is founder-led by CEO Joseph C. Belanoff, M.D., who co-founded the company in 1998 and has steered it through Korlym's 2012 approval and commercialization, demonstrating a proven track record in niche endocrinology.[1]
Insider ownership remains aligned with shareholders, supporting prudent capital allocation like maintaining zero debt and $372 million in cash for R&D without dilution; no major missteps in deployment noted recently.[1][3]
Key Risks
Regulatory and pipeline risks loom large, as Korlym's dominance relies on trial successes for relacorilant—recent Q4 2025 earnings miss highlights execution vulnerability, with Phase 3 oncology readouts critical for diversification.[1][2]
Patent and generic competition threatens post-2037, potentially eroding 95%+ of revenue; limited diversification exposes the business to rapid market share loss if alternatives emerge.[1]
Operational profitability pressures persist, with operating margins plunging to 2.2% in Q4 2025 from rising R&D and SG&A amid slowing growth, straining cash flow if expenses outpace sales.[1]
Sources